Comment

  • 30 May 2018

    Another BACE1 failure in Alzheimer’s: too little, too late?

    Johnson & Johnson’s Janssen division has decided to halt the Phase II–III EARLY clinical trial (NCT02569398) of its Alzheimer’s disease (AD) candidate atabacestat (JNJ-54861911), a Beta-Secretase (BACE) inhibitor, due to safety...

Close
Close
Close

Go Top